Professional societies have led the unenviable challenge of clarifying recommendations on management prioritization for breast cancer during this COVID‐19 pandemic.[^1^](#tbj13961-bib-0001){ref-type="ref"}, [^2^](#tbj13961-bib-0002){ref-type="ref"}, [^3^](#tbj13961-bib-0003){ref-type="ref"}, [^4^](#tbj13961-bib-0004){ref-type="ref"}, [^5^](#tbj13961-bib-0005){ref-type="ref"}, [^6^](#tbj13961-bib-0006){ref-type="ref"} Triage recommendations estimate the risk of delay‐related outcome compromise. Interventions span deferment, simplification, reorganization of treatment sequence,[^7^](#tbj13961-bib-0007){ref-type="ref"} to pure neo‐adjuvant endocrine therapy in centers with substantial constraints.[^8^](#tbj13961-bib-0008){ref-type="ref"} However, treatment delay can still result in disease upstage, limit surgical options, intensify neo‐adjuvant and adjuvant treatment, and decrease survival.[^9^](#tbj13961-bib-0009){ref-type="ref"} Singapore reported its first imported COVID‐19 case on 23rd January 2020. To confront the evolving situation, Sengkang General Hospital\'s (SKH) breast unit mobilized a "triple algorithm" approach (Figure [1](#tbj13961-fig-0001){ref-type="fig"}), aimed at delivering optimal breast cancer management despite pandemic constraints.

!["Triple Algorithm" approach to pandemic breast cancer management](TBJ-9999-na-g001){#tbj13961-fig-0001}

Our retrospective cohort study compared women with breast carcinoma who presented during the peri‐pandemic period versus similar months from 1st January to 30th April 2019. Patients were identified from our joint breast cancer prospective database. Ethical approval was obtained from Centralized Institutional Review Board Singhealth (Ref: 2019/2419). Summary statistics were calculated, outcomes compared using Pearson Chi‐squared or Fisher Exact test for categorical variables and Mann‐Whitney *U* for continuous variables. *P* values \< .05 were considered statistically significant.

In 2020, 303 new patients attended, compared to 400 in 2019. We studied 97 breast carcinoma patients. There was a 24% decrease in new cases and a statistically insignificant 27% decrease in cancer diagnoses (*P = *.486; Figure [2](#tbj13961-fig-0002){ref-type="fig"}). More had T4 disease (19.5% vs 3.6%; *P = *.026), otherwise patient characteristics, stage, and cancer biology were similar and reflective of the national registry\'s distribution [^10^](#tbj13961-bib-0010){ref-type="ref"} (Table [1](#tbj13961-tbl-0001){ref-type="table"}). Fewer underwent upfront surgery (*56.1% vs 78.6%; P = .040*), more commenced neo‐adjuvant therapy (29.3% vs 10.7%; *P = *.040), possibly because of locally advanced disease. There was no significant difference in duration from operation listing to surgery. Peri‐pandemic, 73.7% of patients had surgery within 1‐week and the rest within 2, possibly related to resource ringfencing. There was no significant difference in surgery type, including subcutaneous mastectomy, reconstruction, and oncoplastic breast conserving surgery (Table [2](#tbj13961-tbl-0002){ref-type="table"}). 68.3% felt none to slight concern that attendance can potentially result in COVID‐19 exposure. A total of 90.3% presented at the earliest opportunity.

![Patients seen at SKH breast centre](TBJ-9999-na-g002){#tbj13961-fig-0002}

###### 

Patient and tumor characteristics

                                     2019 \[n = 56 (%)\]   2020 \[n = 41 (%)\]                                 *P* value
  ---------------------------------- --------------------- --------------------------------------------------- -----------
  Age                                                                                                          .363
  \<30                               0 (0%)                1 (2.4%)                                            
  30‐39                              5 (8.9%)              2 (4.9%)                                            
  40‐49                              9 (16.1%)             9 (22.0%)                                           
  50‐59                              18 (32.1%)            6 (14.6%)                                           
  60‐70                              15 (26.8%)            13 (31.7%)                                          
  \>70                               9 (16.1%)             10 (24.4%)                                          
  Comorbidities                                                                                                .141
  None                               37 (66.1%)            21 (51.2%)                                          
  Chronic                            19 (33.9%)            20 (48.8%)                                          
  Presentation                                                                                                 .196
  Symptomatic                        47 (83.9%)            38 (92.7%)                                          
  Incidental/Screen‐detected         9 (16.1%)             3 (7.3%)                                            
  Modality of incidental detection   n = 9                 n = 3                                               .414
  Examination                        1 (11.1%)             0                                                   
  Mammography                        4 (44.5%)             3 (100%)                                            
  Ultrasonography                    2 (22.2%)             0                                                   
  CT                                 2 (22.2%)             0                                                   
  Duration of Symptoms (wk)                                                                                    .596
  \<2                                17                    9                                                   
  2‐4                                12                    10                                                  
  ≥4                                 27                    20                                                  
  Nonbreast                          0                     2                                                   
  T Stage                                                                                                      **.026**
  Tis                                1 (1.8%)              3 (7.3%)                                            
  T1                                 18 (32.1%)            11 (26.8%                                           
  T2                                 25 (44.6%)            17 (41.5%)                                          
  T3                                 10 (17.9%)            2 (4.9%)                                            
  T4                                 2 (3.6%)              8 (19.5%)                                           
  N Stage                                                                                                      .124
  N0                                 26 (46.4%)            23 (56.1%)                                          
  N1                                 24 (42.9%)            10 (24.4%)                                          
  N2                                 6 (10.7%)             6 (4.6%)                                            
  N3                                 0 (0%)                2 (4.9%)                                            
  M Stage                                                                                                      .562
  M0                                 50 (89.3%)            35 (85.4%)                                          
  M1                                 6 (10.7%)             6 (14.6%)                                           
  TNM Stage                                                                                                    .649
  0                                  1 (1.8%)              3 (7.3%)                                            
  1                                  14 (25.0%)            10 (24.4%)                                          
  2                                  24 (42.9%)            16 (39.0%)                                          
  3                                  11 (19.6%)            6 (14.6%)                                           
  4                                  6 (10.7%)             6 (14.6%)                                           
  Bloom‐Richardson Grade                                                                                       .840
  G1                                 3 (5.4%)              2 (4.9%)                                            
  G2                                 26 (46.4%)            21 (51.2%)                                          
  G3                                 27 (48.2%)            16 (39.0%)                                          
  NA                                 0 (0%)                1 (2.5%)[^a^](#tbj13961-note-0001){ref-type="fn"}   
  Estrogen Receptor                                                                                            .748
  ER‐Positive                        45 (80.4%)            34 (82.9%)                                          
  ER‐Negative                        11 (19.6%)            7 (17.1%)                                           
  Progesterone Receptor                                                                                        .811
  PR‐Positive                        36 (64.3%)            26 (63.4%)                                          
  PR‐Negative                        20 (35.7%)            13 (31.7%)                                          
  NA (DCIS)                          0 (0%)                2 (4.9%)                                            
  HER2 Status                                                                                                  .664
  HER2‐Positive                      20 (35.7%)            12 (29.3%)                                          
  HER2‐Negative                      35 (62.5%)            25 (61.0%)                                          
  NA (DCIS)                          1 (1.8%)              4 (9.8%)                                            
  Biology                                                                                                      .551
  Luminal A                          32 (57.1%)            24 (58.5%)                                          
  Luminal B                          12 (21.4%)            9 (22.0%)                                           
  Her2 Positive                      8 (14.3%)             3 (7.3%)                                            
  Basal Type                         4 (7.1%)              5 (12.2%)                                           

Bold indicates values of significance.

Core biopsy at another center, grade not reported, referred after NAST.
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###### 

Treatment

                                                          2019 \[n (1%)\]                                       2020 \[n (1%)\]                                       *P* value
  ------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- -----------
  Initial Treatment Offered                               n = 56                                                n = 41                                                **.040**
  Surgery                                                 44 (78.6%)[^a^](#tbj13961-note-0002){ref-type="fn"}   23 (56.1%)[^b^](#tbj13961-note-0003){ref-type="fn"}   
  Neoadjuvant Systemic Therapy                            6 (10.7%)                                             12 (29.3%)                                            
  Palliation                                              6 (10.7%)                                             6 (14.6%)                                             
  Duration from time of listing to upfront surgery (wk)   n = 44                                                n = 19                                                .909
  \<1                                                     2 (4.5%)                                              0 (0%)                                                
  1                                                       25 (56.9%)                                            14 (73.7%)                                            
  2                                                       12 (27.3%)                                            5 (26.3%)                                             
  3                                                       3 (6.8%)                                              0 (0%)                                                
  ≥4                                                      2 (4.5%)                                              0 (0%)                                                
  Surgery                                                 n = 47                                                n = 20                                                .244
  Simple Mastectomy                                       27 (57.5%)                                            9 (45.0%)                                             
  Skin‐/Nipple‐Sparing Mastectomy                         4 (8.5%)                                              3 (15.0%)                                             
  Breast Conserving Surgery                               11 (23.4%)                                            5 (25.0%)                                             
  Oncoplastic Surgery                                     5 (10.6%)                                             3 (15.0%)                                             
  Reconstruction                                          n = 4                                                 n = 3                                                 .350
  Implant‐based                                           1                                                     0                                                     
  Pedicled‐TRAM                                           3                                                     2                                                     
  DIEP                                                    0                                                     1                                                     
  Oncoplastic Breast Surgery                              n = 5                                                 n = 3                                                 
  Mastopexy/Mammoplasty                                   4                                                     2                                                     .643
  LIPCAP/AICAP Flap                                       1                                                     1                                                     

Bold indicates values of significance.

1 underwent treatment at another center;2 declined curative treatment.

1 declined standard treatment; 2 returned to home country.
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Our study\'s limitations include its small size and retrospective nature. The breast unit is within early phases of development, recently accepting patients since August 2018. In 2019, we were only 5‐8 months old; the 2020 data reflects a slightly more established 1.5‐year‐old hospital with 2 full‐time consultant breast surgeons. We cannot infer that the two groups are directly comparable nor results generalizable. We look forward to further study of potential rebound effect, and collaboration with other local and regional hospitals.

Breast cancer remains the most common cancer in Singapore.[^10^](#tbj13961-bib-0010){ref-type="ref"} Optimization and delivery of gold‐standard management can minimize the postpandemic tsunami of backlog cases. Reflection guides our postpandemic responses and can streamline future approaches for emergency response preparedness. Guidelines should accommodate individualized considerations for patient, tumor, and systemic factors unique to the practicing environment. Collectively, we aim to create a safe environment for both staff and patients, deliver timely intervention for those in need while battling the pandemic for the greater good.
